Integer (ITGR) versus Arch Therapeutics (ARTH) Critical Analysis
Integer (NYSE: ITGR) and Arch Therapeutics (OTCMKTS:ARTH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.
Earnings and Valuation
This table compares Integer and Arch Therapeutics’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Integer||$1.39 billion||1.06||$5.96 million||$0.63||73.81|
|Arch Therapeutics||N/A||N/A||-$7.78 million||($0.05)||-9.00|
Integer has higher revenue and earnings than Arch Therapeutics. Arch Therapeutics is trading at a lower price-to-earnings ratio than Integer, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
95.0% of Integer shares are owned by institutional investors. Comparatively, 0.0% of Arch Therapeutics shares are owned by institutional investors. 4.8% of Integer shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Risk & Volatility
Integer has a beta of 1.07, suggesting that its stock price is 7% more volatile than the S&P 500. Comparatively, Arch Therapeutics has a beta of 4.53, suggesting that its stock price is 353% more volatile than the S&P 500.
This is a summary of recent recommendations and price targets for Integer and Arch Therapeutics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Integer presently has a consensus price target of $51.00, indicating a potential upside of 9.68%. Arch Therapeutics has a consensus price target of $2.83, indicating a potential upside of 529.63%. Given Arch Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Arch Therapeutics is more favorable than Integer.
This table compares Integer and Arch Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Integer beats Arch Therapeutics on 8 of the 12 factors compared between the two stocks.
Greatbatch, Inc. is a developer and manufacturer of medical devices and components. The Company operates through two segments: Greatbatch Medical and QiG Group (QiG). Greatbatch Medical designs and manufactures products where the Company either owns the intellectual property or has unique manufacturing and assembly expertise. Greatbatch Medical’s products include medical devices and components for the cardiac, neuromodulation, orthopedics, portable medical, vascular and energy markets. QiG focuses on developing medical device systems for some of healthcare’s challenges and reflects the Company’s strategic evolution of its product offerings in order to raise the growth and profitability profile of the Company. QiG utilizes a diversified portfolio approach with three investment modes: new medical device systems commercialization, collaborative programs with OEM customers and strategic equity positions in emerging healthcare companies.
About Arch Therapeutics
Arch Therapeutics, Inc. is a development-stage company. The Company operates as a biotechnology company. The Company focuses on developing products to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. The Company’s technology is based on a self-assembling peptide that creates a physical, mechanical barrier, which could be applied to seal organs or wounds that are leaking blood and other fluids. The Company’s primary product candidates, collectively known as the AC5 Devices (AC5), are designed to achieve hemostasis in surgical procedures. The Company’s product candidates rely on its self-assembling peptide technology and are designed to achieve hemostasis in skin wounds, and minimally invasive and open surgical procedures. The Company focuses on developing other product candidates based on its technology platform for use in a range of indications. As of September 30, 2016, the Company had not generated any revenues.
Receive News & Ratings for Integer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integer and related companies with Analyst Ratings Network's FREE daily email newsletter.